Hydroxymethylglutaryl-CoA Reductase Inhibitors

"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.

Descriptor ID	D019161
MeSH Number(s)	D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
Concept/Terms	Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl CoA Reductase Inhibitors Inhibitors, Hydroxymethylglutaryl-CoA Reductase Reductase Inhibitors, Hydroxymethylglutaryl-CoA Inhibitors, HMG-CoA Reductase Inhibitors, HMG CoA Reductase Reductase Inhibitors, HMG-CoA HMG-CoA Reductase Inhibitors HMG CoA Reductase Inhibitors Statins, HMG-CoA HMG-CoA Statins Statins, HMG CoA Inhibitors, Hydroxymethylglutaryl-CoA Hydroxymethylglutaryl-CoA Inhibitors Inhibitors, Hydroxymethylglutaryl CoA Statins Inhibitors, Hydroxymethylglutaryl-Coenzyme A Hydroxymethylglutaryl-Coenzyme A Inhibitors Inhibitors, Hydroxymethylglutaryl Coenzyme A

Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Hypolipidemic Agents [D27.505.519.186.071]
Anticholesteremic Agents [D27.505.519.186.071.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.186.071.202.370]
Enzyme Inhibitors [D27.505.519.389]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.389.370]
Therapeutic Uses [D27.505.954]
Lipid Regulating Agents [D27.505.954.557]
Hypolipidemic Agents [D27.505.954.557.500]
Anticholesteremic Agents [D27.505.954.557.500.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.954.557.500.202.370]

Below are MeSH descriptors whose meaning is related to "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 531 publications over 28 distinct years, with a maximum of 46 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	2	0	2
1993	1	0	1
1994	1	1	2
1996	1	3	4
1997	1	1	2
1998	3	0	3
1999	2	1	3
2000	3	1	4
2001	3	0	3
2002	7	2	9
2003	10	7	17
2004	14	7	21
2005	20	1	21
2006	19	6	25
2007	22	8	30
2008	21	4	25
2009	22	3	25
2010	22	4	26
2011	22	9	31
2012	17	4	21
2013	28	5	33
2014	30	15	45
2015	25	9	34
2016	23	13	36
2017	17	6	23
2018	26	6	32
2019	33	13	46
2020	3	4	7

Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.

Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundström T, Agrawal R, Menon V, Wolski K, Nissen SE. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020 12 08; 324(22):2268-2280.

View in: PubMed
Mahtta D, Ramsey DJ, Al Rifai M, Nasir K, Samad Z, Aguilar D, Jneid H, Ballantyne CM, Petersen LA, Virani SS. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.

View in: PubMed
Hussain A, Ballantyne CM, Saeed A, Virani SS. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.

View in: PubMed
Lowenstern A, Li S, Virani SS, Navar AM, Li Z, Robinson JG, Roger VL, Goldberg AC, Koren A, Louie MJ, Peterson ED, Wang TY. Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. Am Heart J. 2020 07; 225:88-96.

View in: PubMed
Balanescu DV, Donisan T, Palaskas N, Lopez-Mattei J, Kim PY, Buja LM, McNamara DM, Kobashigawa JA, Durand JB, Iliescu CA. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. Cardiovasc Pathol. 2020 Jul - Aug; 47:107211.

View in: PubMed
Walther CP, Richardson PA, Virani SS, Winkelmayer WC, Navaneethan SD. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant. 2020 02 01; 35(2):312-319.

View in: PubMed
Cristea S, Coles GL, Hornburg D, Gershkovitz M, Arand J, Cao S, Sen T, Williamson SC, Kim JW, Drainas AP, He A, Cam LL, Byers LA, Snyder MP, Contrepois K, Sage J. The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer. Cancer Res. 2020 03 15; 80(6):1293-1303.

View in: PubMed
Rifai MA, Blaha MJ, Patel J, Xiaoming J, Cainzos-Achirica M, Greenland P, Budoff M, Yeboah J, Nasir K, Al-Mallah MH, Virani SS. Coronary Artery Calcification, Statin Use and Long-Term Risk of Atherosclerotic Cardiovascular Disease Events (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2020 03 15; 125(6):835-839.

View in: PubMed
Jia X, Ramsey DJ, Rifai MA, Ahmed ST, Akeroyd JM, Dixon DL, Gluckman TJ, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.

View in: PubMed
Menon V, Kumar A, Patel DR, John JS, Wolski KE, McErlean E, Riesmeyer JS, Weerakkody G, Ruotolo G, Cremer PC, Nicholls SJ, Lincoff AM, Nissen SE. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy. J Am Heart Assoc. 2020 01 07; 9(1):e014328.

View in: PubMed

People

Explore

Similar Concepts

Top Journals